Blood lymphocyte subsets identify optimal responders to IFN-beta in MS-Reference-Cited by-同舟云学术

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS

Published:2017-10-12 Issue:1 Volume:265 Page:24-31
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Alenda Raquel,Costa-Frossard Lucienne,Alvarez-Lafuente Roberto,Espejo Carmen,Rodríguez-Martín Eulalia,de la Maza Susana Sainz,Villarrubia Noelia,Río Jordi,Domínguez-Mozo María I.,Montalban Xavier,Álvarez-Cermeño José C.,Villar Luisa M.^ORCID

Funder

Instituto de Salud Carlos III

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/article/10.1007/s00415-017-8625-6/fulltext.html

Reference27 articles.

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

2. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294

3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) (1998) Study group randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

4. Einarson TR, Bereza BG, Machado M (2017) Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. Curr Med Res Opin 33:579–593

5. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4:329–333

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis;Journal of Neuroinflammation;2022-11-19

2. Development and certification of a pharmacopoeial reference standard for primary structure identification of purified recombinant interferon beta-1b by peptide mapping;Biological Products. Prevention, Diagnosis, Treatment;2022-04-09

3. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab;Frontiers in Immunology;2021-10-08

4. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients;Journal of Neurology;2021-10-01

5. CD4+ and CD25+ T‐cell response to short‐time interferon‐beta therapy on IL10, IL23A and FOXP3 genes in multiple sclerosis patients;International Journal of Clinical Practice;2021-04-29